These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD. Moraru A; Pînzaru G; Moţoc A; Costin D; Brănişteanu D Rom J Ophthalmol; 2017; 61(3):207-211. PubMed ID: 29450400 [No Abstract] [Full Text] [Related]
14. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465 [TBL] [Abstract][Full Text] [Related]
15. Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting. Vo Kim S; Fajnkuchen F; Sarda V; Qu-Knafo L; Bodaghi B; Giocanti-Aurégan A Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2165-2171. PubMed ID: 28831613 [TBL] [Abstract][Full Text] [Related]
16. Long-term intraocular pressure changes after intravitreal injection of bevacizumab. Baek SU; Park IW; Suh W Cutan Ocul Toxicol; 2016 Dec; 35(4):310-4. PubMed ID: 26820610 [TBL] [Abstract][Full Text] [Related]
17. Sustained Elevation of Intraocular Pressure After Administration of Intravitreal Anti-Vascular Endothelial Growth Factor Agents in Patients With and Without Pseudoexfoliation Syndrome. Ucgul AY; Aktas Z; Ozgur A; Cubuk MO; Hasanreisoglu M; Ozdek S; Gurelik G J Glaucoma; 2020 Oct; 29(10):981-988. PubMed ID: 32649449 [TBL] [Abstract][Full Text] [Related]
18. INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Storey PP; Ho V; Yeh S; Reddy S; Fang-Yen NH; Pequignot E; Leiby BE; Fineman M; Garg S; Hubbard GB; Hsu J Retina; 2015 Oct; 35(10):1992-2000. PubMed ID: 26035396 [TBL] [Abstract][Full Text] [Related]
19. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. Bakri SJ; Moshfeghi DM; Francom S; Rundle AC; Reshef DS; Lee PP; Schaeffer C; Rubio RG; Lai P Ophthalmology; 2014 May; 121(5):1102-8. PubMed ID: 24393349 [TBL] [Abstract][Full Text] [Related]
20. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. Bressler SB; Almukhtar T; Bhorade A; Bressler NM; Glassman AR; Huang SS; Jampol LM; Kim JE; Melia M; JAMA Ophthalmol; 2015 May; 133(5):589-97. PubMed ID: 25719991 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]